Pfizer Inc. which can be found using ticker (PFE) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $50.00 and $23.00 with the average share target price sitting at $32.38. (at the time of writing). Now with the previous closing price of $29.73 this now indicates there is a potential upside of 8.9%. The 50 day moving average now sits at $29.41 while the 200 day moving average is $34.98. The company has a market capitalization of 167.87B. The stock price for the company is currently $29.09 USD
The potential market cap would be $182,830,906,968 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 16.25, revenue per share of $12.16 and a 2.39% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
